Seres Therapeutics Inc (MCRB)

Feb 06, 2025

Seres Therapeutics expands board, appoints new director - Investing.com India

Feb 06, 2025

Feb 06, 2025

Check Out Seres Therapeutics Inc (MCRB)’s Trade Data Rather Than the Analysts’ Views - SETE News

Feb 06, 2025

Feb 06, 2025

Seres Therapeutics Expands Board with Nestlé’s Appointee - TipRanks

Feb 06, 2025

Feb 05, 2025

Recent Insider Activity Suggests Potential Gains for Seres Therapeutics Inc (MCRB) - Knox Daily

Feb 05, 2025

Feb 04, 2025

A year in review: Seres Therapeutics Inc (MCRB)’s performance in the last year - US Post News

Feb 04, 2025

Jan 31, 2025

Seres Therapeutics (NASDAQ:MCRB) Shares Cross Below 50-Day Moving AverageTime to Sell? - MarketBeat

Jan 31, 2025

Jan 23, 2025

Investors in Seres Therapeutics (NASDAQ:MCRB) from three years ago are still down 88%, even after 17% gain this past week - Simply Wall St

Jan 23, 2025

Jan 20, 2025

**Seres Therapeutics, Inc. Posts Updated Corporate Presentation – 8-K Filing Review**** - Defense World

Jan 20, 2025

Jan 17, 2025

Seres Therapeutics receives $50 million from Nestlé Health Science By Investing.com - Investing.com Australia

Jan 17, 2025

Jan 17, 2025

Seres Therapeutics receives $50 million from Nestlé Health Science - MSN

Jan 17, 2025

Jan 17, 2025

Microbiomes Market to Grow by USD 1.13 Billion (2024-2028), Driven by Rising Disease Prevalence; AI Impact on Market TrendsTechnavio - The Malaysian Reserve

Jan 17, 2025

Jan 16, 2025

Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale - The Manila Times

Jan 16, 2025

Jan 16, 2025

Seres Therapeutics Receives $50M Payment from Nestlé, Extends Cash Runway to 2026 - StockTitan

Jan 16, 2025

Jan 13, 2025

Seres Therapeutics Strengthens Future with VOWST Sale - TipRanks

Jan 13, 2025

Jan 13, 2025

Seres Therapeutics Provides Corporate Updates and Financial Results - Defense World

Jan 13, 2025

Jan 11, 2025

Seres Therapeutics (NASDAQ:MCRB) Downgraded by StockNews.com to “Sell” - Defense World

Jan 11, 2025

Jan 11, 2025

StockNews.com Downgrades Seres Therapeutics (NASDAQ:MCRB) to Sell - MarketBeat

Jan 11, 2025

Jan 10, 2025

Seres announces new translational biomarker results from SER-155 Phase 1b study - Yahoo Finance

Jan 10, 2025

Jan 10, 2025

Geode Capital Management LLC Acquires 255,014 Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) - Defense World

Jan 10, 2025

Jan 09, 2025

Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates - The Manila Times

Jan 09, 2025

Jan 09, 2025

Seres Therapeutics Announces New Translational Biomarker - GlobeNewswire

Jan 09, 2025

Jan 09, 2025

Seres' SER-155 Shows Breakthrough Results in Stem Cell Transplant Study, FDA Fast-Track Follows - StockTitan

Jan 09, 2025

Jan 04, 2025

State Street Corp Purchases 43,700 Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) - Defense World

Jan 04, 2025

Jan 04, 2025

Seres Therapeutics (NASDAQ:MCRB) Rating Increased to Hold at StockNews.com - Defense World

Jan 04, 2025

Jan 03, 2025

Seres Therapeutics (NASDAQ:MCRB) Raised to Hold at StockNews.com - MarketBeat

Jan 03, 2025

Jan 02, 2025

Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Above 50 Day Moving AverageTime to Sell? - MarketBeat

Jan 02, 2025

Jan 02, 2025

5 Best Microbiome Companies (January 2025) - Securities.io

Jan 02, 2025

Dec 26, 2024

The past three years for Seres Therapeutics (NASDAQ:MCRB) investors has not been profitable - Yahoo Finance

Dec 26, 2024

Dec 19, 2024

Charles Schwab Investment Management Inc. Has $708,000 Stake in Seres Therapeutics, Inc. (NASDAQ:MCRB) - Defense World

Dec 19, 2024

Dec 18, 2024

Seres Therapeutics (NASDAQ:MCRB) Stock Price Passes Below 200 Day Moving AverageHere's What Happened - MarketBeat

Dec 18, 2024

Dec 17, 2024

Seres Therapeutics to highlight plans for SER-155 at JPMorgan conference - Yahoo Finance

Dec 17, 2024

Dec 16, 2024

Biotech Biz Xilio Therapeutics Appoints Chief Legal Officer - Law360

Dec 16, 2024

Dec 16, 2024

Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer - citybiz

Dec 16, 2024

Dec 16, 2024

Xilio Therapeutics Strengthens Leadership Team, Appoints Seres Therapeutics Veteran as Chief Legal Officer - StockTitan

Dec 16, 2024

Dec 16, 2024

Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference - The Manila Times

Dec 16, 2024

Dec 16, 2024

Seres Therapeutics' Breakthrough Therapy Cuts Infection Risk by 77% in Stem Cell Transplants - StockTitan

Dec 16, 2024

Dec 11, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TTNP, MCRB, LLAP on Behalf of Shareholders - The Eastern Progress Online

Dec 11, 2024

Dec 10, 2024

Seres’ SER-155 gains breakthrough status for BSIs reduction - Yahoo Finance

Dec 10, 2024

Dec 09, 2024

MCRBSeres Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Dec 09, 2024

Dec 09, 2024

FDA Grants Breakthrough Therapy Designation to Seres Therapeutics' SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) - The Manila Times

Dec 09, 2024

Dec 09, 2024

FDA Grants Breakthrough Therapy Designation to Seres - GlobeNewswire

Dec 09, 2024

Dec 09, 2024

Seres' SER-155 Wins FDA Breakthrough Status After Stunning 77% Infection Reduction in Transplant Study - StockTitan

Dec 09, 2024

Nov 27, 2024

Seres Therapeutics (NASDAQ:MCRB) Downgraded to "Sell" Rating by StockNews.com - MarketBeat

Nov 27, 2024

Nov 22, 2024

Seres Therapeutics to Participate in Piper Sandler Healthcare Conference - The Manila Times

Nov 22, 2024

Nov 22, 2024

Seres Therapeutics CEO to Present at Piper Sandler Healthcare Conference | MCRB Stock News - StockTitan

Nov 22, 2024

Nov 20, 2024

Seres Therapeutics CEO Eric Shaff sells shares worth $1,354 By Investing.com - Investing.com Nigeria

Nov 20, 2024